Simplicispira hankyongi strain:NY-02
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA489338 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Pseudomonas sp. strain CK-NBRI-02 is a potential plant growth-promoting Gram-negative rhizobacterium isolated from the rhizosphere of maize plants growing in fields in Srinagar, Jammu, and Kashmir, India. Here, we report a 5.25-Mb draft assembly of the genome sequence of Pseudomonas sp. strain CK-NBRI-02 with an average G+C content of 62.47%.
2019-01-01 | S-EPMC6813394 | BioStudies
Project description:Here, we report the first complete genome sequence of the Mycobacterium intracellulare clinical strain MOTT-02, which was previously grouped in the INT2 genotype of M. intracellulare. This genome sequence will serve as a valuable reference for improving the understanding of the disparity in the virulence and epidemiologic traits between M. intracellulare genotypes.
2012-01-01 | S-EPMC3347180 | BioStudies
Project description:Bacillus thuringiensis (Bt) is widely used to control agricultural and forestry pests, though there are only a few available complete genome sequences of the Bt reference strain. Here, we report the complete genome sequence of B. thuringiensis serovar rongseni reference strain SCG04-02, which is toxic to Plutella xylostella.
2017-01-01 | S-EPMC5624745 | BioStudies
Project description:Fluoribacter dumoffii NY 23 strain:NY 23 Genome sequencing and assembly
| PRJNA74015 | ENA
Project description:Adoptive immunotherapy of tumors with T cells specific for the cancer-testis antigen NY-ESO-1 has shown great promise in preclinical models and in early stage clinical trials. Tumor persistence or recurrence after NY-ESO-1-specific therapy occurs, however, and the mechanisms of recurrence remain poorly defined. In a murine xenograft model of NY-ESO-1(+) multiple myeloma, we observed tumor recurrence after adoptive transfer of CD8(+) T cells genetically redirected to the prototypic NY-ESO-1157-165 peptide presented by HLA-A*02:01. Analysis of the myeloma cells that had escaped from T-cell control revealed intact expression of NY-ESO-1 and B2M, but selective, complete loss of HLA-A*02:01 expression from the cell surface. Loss of heterozygosity (LOH) in the major histocompatibility complex (MHC) involving the HLA-A locus was identified in the tumor cells, and further analysis revealed selective loss of the allele encoding HLA-A*02:01. Although LOH involving the MHC has not been described in myeloma patients with persistent or recurrent disease after immune therapies such as allogeneic hematopoietic cell transplantation (HCT), it has been described in patients with acute myelogenous leukemia who relapsed after allogeneic HCT. These results suggest that MHC loss should be evaluated in patients with myeloma and other cancers who relapse after adoptive NY-ESO-1-specific T-cell therapy.
2014-01-01 | S-EPMC4040020 | BioStudies
Project description:We report the draft genome sequence of a marine bacterium, Bacillus sp. strain 007/AIA-02/001, isolated from the marine sponge Coelocarteria singaporensis, obtained from water off the coast of Singapore. The analysis of the bacterial genome using the bioinformatics tool antiSMASH 4.0.2 showed the presence of a number of unique natural product biosynthetic pathways.
2019-01-01 | S-EPMC6715860 | BioStudies
Project description:This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM) evaluated the safety and activity of autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) that recognizes a peptide shared by cancer antigens New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and L-antigen family member 1 (LAGE-1) and presented by HLA-A*02:01. T cells collected from 25 HLA-A*02:01-positive patients with MM expressing NY-ESO-1 and/or LAGE-1 were activated, transduced with self-inactivating lentiviral vector encoding the NY-ESO-1c259TCR, and expanded in culture. After myeloablation and autologous stem cell transplant (ASCT), all 25 patients received an infusion of up to 1 × 1010 NY-ESO-1 specific peptide enhanced affinity receptor (SPEAR) T cells. Objective response rate (International Myeloma Working Group consensus criteria) was 80% at day 42 (95% confidence interval [CI], 0.59-0.93), 76% at day 100 (95% CI, 0.55-0.91), and 44% at 1 year (95% CI, 0.24-0.65). At year 1, 13/25 patients were disease progression-free (52%); 11 were responders (1 stringent complete response, 1 complete response, 8 very good partial response, 1 partial response). Three patients remained disease progression-free at 38.6, 59.2, and 60.6 months post-NY-ESO-1 SPEAR T-cell infusion. Median progression-free survival was 13.5 months (range, 3.2-60.6 months); median overall survival was 35.1 months (range, 6.4-66.7 months). Infusions were well tolerated; cytokine release syndrome was not reported. No fatal serious adverse events occurred during study conduct. NY-ESO-1 SPEAR T cells expanded in vivo, trafficked to bone marrow, demonstrated persistence, and exhibited tumor antigen-directed functionality. In this MM patient population, NY-ESO-1 SPEAR T-cell therapy in the context of ASCT was associated with antitumor activity. This trial was registered at www.clinicaltrials.gov as #NCT01352286.
2019-01-01 | S-EPMC6616263 | BioStudies
Project description:Investigation of whole genome gene expression differences in a full (nine-gene) Lsr locus knockout strain compared to the wild-type strain (CZ4126/02). This Lsr mutant is unable to import the autoinducer-2 (AI-2) quorum sensing molecule nor mediate any potential LsrR-based transcriptional regulation. WT and Lsr-KO strains were grown in two different media to two or three different time-points. RNA was extracted from these sampling conditions in two separate cultures (biological replicates). Each of these RNA samples was run on two different H. influenzae supragenome arrays (technical replicates). 3-13 probes represent each subcluster (gene) and two replicate probe sets are included on each custom NTHi supragenome chip. Thus, under each sampling condition, 8 separate values are obtained per strain and used for WT:Lsr-KO comparisons.
2012-10-19 | E-GEOD-41690 | BioStudies
Project description:In this study, through a multistep enrichment and isolation procedure, a halophilic bacterial strain was isolated from unpolluted saline soil, which was able to effectively and preferentially degrade long chain alkanes (especially tetracosane and octacosane). The strain was identified by 16S rRNA gene sequence as an Alcanivorax sp. The growth of strain Est-02 was optimized at the presence of tetracosane in different NaCl concentrations, temperatures, and pH. The consumption of different heavy alkanes was also investigated. Optimal culture conditions of the strain were determined to be as follows: 10% NaCl, temperature 25-35 °C and pH 7. Alcanivorax sp. strain Est-02 was able to use a wide range of aliphatic substrates ranging from C14 to C28 with clear tendency to utilize heavy chain hydrocarbons of C24 and C28. During growth on a mixture of alkanes (C14-C28), the strain consumed 60% and 65% of tetracosane and octacosane, respectively, while only about 40% of the lower chain alkanes were degraded. This unique ability of the strain Est-02 in efficient and selective biodegradation of long chain hydrocarbons could be further exploited for remediation of wax and heavy oil contaminated soils or upgrading of heavy crude oils. Comparison of the sequence of alkane hydroxylase gene (alkB) of strain Est-02 with previously reported sequences for Alcanivorax spp. and other hydrocarbon degraders, showed a remarkable phylogenetic distance between the sequence alkB of Est-02 and other alkane-degrading bacteria.
2019-01-01 | S-EPMC6420517 | BioStudies
Project description:To discover novel regulators that influence avermectin biosynthesis, comparative transcriptome analysis between wild-type strain ATCC31267 and avermectin overproducing strain 76-02-e were performed to reveal some differentially expressed genes. Global gene expression in ATCC31267 and 76-02-e was measured at day 2 (early exponential phase) or day 6 (stationary phase), respectively. Three independent experiments for 76-02-e and one for ATCC31267 were performed at each condition.
2013-05-24 | E-GEOD-47223 | ArrayExpress